In addition, the Kruskal-Wallis test also validated the expression levels of DEGs common to T2DM and COPD in different immune cells, and although SUMF2 was expressed at a lower level in immune cells, by combining the RT-qPCR data of Figure 7E T2DM combined with COPD patients, it was found that compared with the healthy individuals, the expression level of SUMF2 alone was statistically different (Figure 9G). This evidence concerns the gene SUMF2 and type 2 diabetes mellitus.